Curated News
By: NewsRamp Editorial Staff
May 14, 2025
NanoViricides, Inc. Updates Antiviral Pipeline with Potential Breakthrough Treatment for Measles and MPox
TLDR
- NanoViricides, Inc. (NYSE American: NNVC) unveils NV-387 as groundbreaking treatment for Measles and MPox, targeting global antiviral market gaps.
- NV-387 by NanoViricides being developed as broad-spectrum antiviral drug for various respiratory infections and pan-herpesvirus treatment, advancing into Phase II clinical trials.
- NanoViricides aims to enhance global antiviral preparedness with NV-387, addressing critical gaps in Measles and MPox treatment to benefit public health worldwide.
- Explore NanoViricides' innovative NV-387 drug candidate for Measles and MPox, offering potential breakthrough in antiviral therapy amid rising global case counts.
Impact - Why it Matters
This news matters as NanoViricides aims to address critical gaps in global antiviral preparedness by developing NV-387 as a treatment for Measles and MPox. With rising global case counts and vaccine failures, the company's strategic update provides hope for effective antiviral solutions in the fight against these diseases.
Summary
NanoViricides, Inc. (NYSE American: NNVC) provided a strategic update on its antiviral pipeline, highlighting NV-387 as a potential breakthrough treatment for Measles and MPox. The company is preparing for animal efficacy studies for Measles and has received clearance for a Phase II Clinical Trial Application for MPox in the DRC. NV-387 is also being developed for broad respiratory infections and pan-herpesvirus treatment to address the lack of approved drugs for Measles and MPox.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, NanoViricides, Inc. Updates Antiviral Pipeline with Potential Breakthrough Treatment for Measles and MPox
